Loading...
Market
How many countries will approve AstraZeneca's FluMist nasal spray vaccine for self-administration by end of 2024?
2
Resolution / Starting Odds
1-5 countries • 25%
6-10 countries • 25%
11-15 countries • 25%
More than 15 countries • 25%
AstraZeneca press releases and regulatory announcements from respective countries
Story
FDA Approves AstraZeneca's FluMist Nasal Spray for Self-Administration on Friday
Sep 20, 2024, 04:25 PM
The U.S. Food and Drug Administration (FDA) announced on Friday the approval of AstraZeneca's FluMist nasal spray vaccine for self- or caregiver-administration. This vaccine is designed to prevent influenza caused by influenza virus subtypes A and B in individuals aged 2 through 49 years. The approval is part of the FDA's broader effort to expand consumer access to medicines and reduce costs and barriers to care. AstraZeneca's FluMist is the first influenza vaccine approved for self-administration, marking a significant milestone in public health.
View original story
Similar markets
0-10 • 25%
11-25 • 25%
26-40 • 25%
41-50 • 25%
Yes • 50%
No • 50%
Less than 1,000 • 25%
1,000-2,000 • 25%
2,000-3,000 • 25%
More than 3,000 • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Less than 10 • 25%
10 to 20 • 25%
20 to 30 • 25%
More than 30 • 25%
Pharmacies • 25%
Online retailers • 25%
Healthcare providers • 25%
Other • 25%
Less than 5% • 25%
5-10% • 25%
10-20% • 25%
More than 20% • 25%
